Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function.

Forrest OA, Chopyk DM, Gernez Y, Brown MR, Conrad CK, Moss RB, Tangpricha V, Peng L, Tirouvanziam R.

J Cyst Fibros. 2019 Jan;18(1):64-70. doi: 10.1016/j.jcf.2018.05.018. Epub 2018 Jun 21.

PMID:
29937317
2.

An alternative cannulation approach for venovenous extracorporeal membrane oxygenation in children for long-term ambulatory support.

Maeda K, Ryan K, Conrad CK, Yarlagadda VV.

J Thorac Cardiovasc Surg. 2018 Jul;156(1):e13-e14. doi: 10.1016/j.jtcvs.2018.03.099. Epub 2018 Apr 3. No abstract available.

PMID:
29685584
3.

Lung clearance index is sensitive to small airway disease in pediatric lung transplant recipients.

Kao JE, Zirbes JM, Conrad CK, Milla CE.

J Heart Lung Transplant. 2017 Sep;36(9):980-984. doi: 10.1016/j.healun.2017.05.004. Epub 2017 May 10.

PMID:
28651906
4.

Current State of Pediatric Lung Transplantation.

Hayes D Jr, Benden C, Sweet SC, Conrad CK.

Lung. 2015 Oct;193(5):629-37. doi: 10.1007/s00408-015-9765-z. Epub 2015 Aug 4.

PMID:
26238859
5.

Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis.

Rosenfeld M, Farrell PM, Kloster M, Swanson JO, Vu T, Brumback L, Acton JD, Castile RG, Colin AA, Conrad CK, Hart MA, Kerby GS, Hiatt PW, Mogayzel PJ, Johnson RC, Davis SD.

Eur Respir J. 2013 Dec;42(6):1545-52. doi: 10.1183/09031936.00138412. Epub 2013 May 30.

6.

Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints.

Davis SD, Rosenfeld M, Kerby GS, Brumback L, Kloster MH, Acton JD, Colin AA, Conrad CK, Hart MA, Hiatt PW, Mogayzel PJ, Johnson RC, Wilcox SL, Castile RG.

Am J Respir Crit Care Med. 2010 Dec 1;182(11):1387-97. doi: 10.1164/rccm.200908-1236OC. Epub 2010 Jul 9.

7.

Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs.

Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, Dunn CE, Davies ZA, Moss RB, Herzenberg LA, Herzenberg LA, Tirouvanziam R.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5779-83. doi: 10.1073/pnas.0813410106. Epub 2009 Mar 17.

8.

Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways.

Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, Davies ZA, Herzenberg LA, Herzenberg LA.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4335-9. doi: 10.1073/pnas.0712386105. Epub 2008 Mar 11.

9.

High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.

Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA.

Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4628-33. Epub 2006 Mar 13.

10.

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.

Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB.

Hum Gene Ther. 2003 Jul 20;14(11):1079-88.

PMID:
12885347
11.

A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.

Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Reynolds TC, Moss RB, Gardner P.

Hum Gene Ther. 2002 Jul 20;13(11):1349-59.

PMID:
12162817
12.

Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P.

Laryngoscope. 1999 Feb;109(2 Pt 1):266-74.

PMID:
10890777
13.

A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.

Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P.

Hum Gene Ther. 1998 Apr 10;9(6):889-909. No abstract available.

PMID:
9581911
14.

Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.

Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M, Barrazza-Ortiz X, Adams R, Askin FB, Carter BJ, Guggino WB, Flotte TR.

Gene Ther. 1996 Aug;3(8):658-68.

PMID:
8854091
15.

In vivo model of adeno-associated virus vector persistence and rescue.

Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, Guggino WB, Cutting GR, Carter BJ, Flotte TR.

J Virol. 1996 May;70(5):3235-41.

16.

Gene therapy vectors as drug delivery systems.

Afione SA, Conrad CK, Flotte TR.

Clin Pharmacokinet. 1995 Mar;28(3):181-9. Review. No abstract available.

PMID:
7758249
17.

Hemothorax in a child as a result of costal exostosis.

Tomares SM, Jabra AA, Conrad CK, Beauchamp N, Phoon CK, Carroll JL.

Pediatrics. 1994 Mar;93(3):523-5. No abstract available.

PMID:
8115223
18.

Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat.

Liddle RA, Green GM, Conrad CK, Williams JA.

Am J Physiol. 1986 Aug;251(2 Pt 1):G243-8.

PMID:
3740265
19.

Regulation of gastric emptying in humans by cholecystokinin.

Liddle RA, Morita ET, Conrad CK, Williams JA.

J Clin Invest. 1986 Mar;77(3):992-6.

Supplemental Content

Loading ...
Support Center